Prostate cancer, version 1.2014.

  title={Prostate cancer, version 1.2014.},
  author={James L. Mohler and Philip W. Kantoff and Andrew James Armstrong and Robert R. Bahnson and M. Cohen and Anthony V. D'Amico and James Andrew Eastham and Charles Enke and Thomas A Farrington and Celestia S. Higano and Eric Mark Horwitz and Mark H. Kawachi and Michael R. Kuettel and Richard W. J. Lee and Gary R Macvicar and Arnold W Malcolm and David Miller and Elizabeth R Plimack and Julio M. Pow-Sang and Sylvia Richey and Mack Roach and Eric M. Rohren and Stan Rosenfeld and Eric Jay Small and S. Srinivas and C I Stein and Seth A. Strope and Jonathan Tward and Patrick Walsh and Dorothy A. Shead and Maria Ho},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  volume={11 12},
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 48 extracted citations


Publications referenced by this paper.
Showing 1-10 of 26 references

Cancer statistics, 2013.

CA: a cancer journal for clinicians • 2013

and Drug Administration

US Foo
Radium-223 dichloride label information. Available at: drugsatfda_docs/label/2013/203971lbl.pdf. Accessed September 13, • 2013

Similar Papers

Loading similar papers…